News from science, research & development.
In our news section you will find current insights into our work, results from ongoing projects, publications and events. Whether it concerns a scientific publication, industry news or an outlook – stay informed.
Latest news.
Mallia Therapeutics reports on novel therapeutic approach for treating alopecia at the annual meeting of the European Hair Research Society (EHRS)
Mallia Therapeutics and Northway Biotech Announce Partnership for the Manufacturing of Soluble CD83 Protein for Hair Loss Treatment
Publications.
CD83 acts as immediate early response gene in activated macrophages and exhibits specific intracellular trafficking properties.
Langguth P, Peckert-Maier K, Beck P, Kuhnt C, Draßner C, Deinzer A, Steinkasserer A, Wild AB.
Biochem Biophys Res Commun. 2023 Mar 5;647:37-46. doi: 10.1016/j.bbrc.2023.01.069. Epub 2023 Jan 23. PMID: 36709671
CD83 expressed by macrophages is an important immune checkpoint molecule for the resolution of inflammation.
Peckert-Maier K, Langguth P, Strack A, Stich L, Mühl-Zürbes P, Kuhnt C, Drassner C, Zinser E, Wrage M, Mattner J, Steinkasserer A, Royzman D, Wild AB.
Front Immunol. 2023 Feb 15;14:1085742. doi: 10.3389/fimmu.2023.1085742. eCollection 2023. PMID: 36875129
Soluble CD83 improves and accelerates wound healing by the induction of pro-resolving macrophages.
Royzman D, Peckert-Maier K, Stich L, König C, Wild AB, Tauchi M, Ostalecki C, Kiesewetter F, Seyferth S, Lee G, Eming SA, Fuchs M, Kunz M, Stürmer EK, Peters EMJ, Berking C, Zinser E, Steinkasserer A.
Front Immunol. 2022 Sep 30;13:1012647. doi: 10.3389/fimmu.2022.1012647. eCollection 2022. PMID: 36248909
The soluble CD83 protein prevents bone destruction by inhibiting the formation of osteoclasts and inducing resolution of inflammation in arthritis.
Royzman D, Andreev D, Stich L, Peckert-Maier K, Wild AB, Zinser E, Mühl-Zürbes P, Jones E, Adam S, Frey S, Fuchs M, Kunz M, Bäuerle T, Nagel L, Schett G, Bozec A, Steinkasserer A.
Front Immunol. 2022 Aug 8;13:936995. doi: 10.3389/fimmu.2022.936995. eCollection 2022. PMID: 36003376
Tilting the Balance: Therapeutic Prospects of CD83 as a Checkpoint Molecule Controlling Resolution of Inflammation.
Peckert-Maier K, Royzman D, Langguth P, Marosan A, Strack A, Sadeghi Shermeh A, Steinkasserer A, Zinser E, Wild AB.
Int J Mol Sci. 2022 Jan 10;23(2):732. doi: 10.3390/ijms23020732. PMID: 35054916
The CD83 Molecule – An Important Immune Checkpoint.
Grosche L, Knippertz I, König C, Royzman D, Wild AB, Zinser E, Sticht H, Muller YA, Steinkasserer A, Lechmann M.
Front Immunol. 2020 Apr 17;11:721. doi: 10.3389/fimmu.2020.00721. eCollection 2020. PMID: 32362900
CD83 orchestrates immunity toward self and non-self in dendritic cells.
Wild AB, Krzyzak L, Peckert K, Stich L, Kuhnt C, Butterhof A, Seitz C, Mattner J, Grüner N, Gänsbauer M, Purtak M, Soulat D, Winkler TH, Nitschke L, Zinser E, Steinkasserer A.
JCI Insight. 2019 Oct 17;4(20):e126246. doi: 10.1172/jci.insight.126246. PMID: 31527313
Endogenous Expression of the Human CD83 Attenuates EAE Symptoms in Humanized Transgenic Mice and Increases the Activity of Regulatory T Cells.
Zinser E, Naumann R, Wild AB, Michalski J, Deinzer A, Stich L, Kuhnt C, Steinkasserer A, Knippertz I.
Front Immunol. 2019 Jun 25;10:1442. doi: 10.3389/fimmu.2019.01442. eCollection 2019. PMID: 31293592
Soluble CD83 Triggers Resolution of Arthritis and Sustained Inflammation Control in IDO Dependent Manner.
Royzman D, Andreev D, Stich L, Rauh M, Bäuerle T, Ellmann S, Boon L, Kindermann M, Peckert K, Bozec A, Schett G, Steinkasserer A, Zinser E.
Front Immunol. 2019 Apr 2;10:633. doi: 10.3389/fimmu.2019.00633. eCollection 2019. PMID: 31001257
CD83 expression is essential for Treg cell differentiation and stability.
Doebbeler M, Koenig C, Krzyzak L, Seitz C, Wild A, Ulas T, Baßler K, Kopelyanskiy D, Butterhof A, Kuhnt C, Kreiser S, Stich L, Zinser E, Knippertz I, Wirtz S, Riegel C, Hoffmann P, Edinger M, Nitschke L, Winkler T, Schultze JL, Steinkasserer A, Lechmann M.
JCI Insight. 2018 Jun 7;3(11):e99712. doi: 10.1172/jci.insight.99712. eCollection 2018 Jun 7. PMID: 29875316
Crystal Structure of the Extracellular Domain of the Human Dendritic Cell Surface Marker CD83.
Heilingloh CS, Klingl S, Egerer-Sieber C, Schmid B, Weiler S, Mühl-Zürbes P, Hofmann J, Stump JD, Sticht H, Kummer M, Steinkasserer A, Muller YA.
J Mol Biol. 2017 Apr 21;429(8):1227-1243. doi: 10.1016/j.jmb.2017.03.009. Epub 2017 Mar 15.PMID: 28315353
Soluble CD83 Inhibits T Cell Activation by Binding to the TLR4/MD-2 Complex on CD14+ Monocytes.
Horvatinovich JM, Grogan EW, Norris M, Steinkasserer A, Lemos H, Mellor AL, Tcherepanova IY, Nicolette CA, DeBenedette MA.
J Immunol. 2017 Mar 15;198(6):2286-2301. doi: 10.4049/jimmunol.1600802. Epub 2017 Feb 13. PMID: 28193829
The Major Immediate-Early Protein IE2 of Human Cytomegalovirus Is Sufficient to Induce Proteasomal Degradation of CD83 on Mature Dendritic Cells.
Heilingloh CS, Grosche L, Kummer M, Mühl-Zürbes P, Kamm L, Scherer M, Latzko M, Stamminger T, Steinkasserer A.
Front Microbiol. 2017 Feb 1;8:119. doi: 10.3389/fmicb.2017.00119. eCollection 2017. PMID: 28203230
Thymic CD4 T cell selection requires attenuation of March8-mediated MHCII turnover in cortical epithelial cells through CD83.
von Rohrscheidt J, Petrozziello E, Nedjic J, Federle C, Krzyzak L, Ploegh HL, Ishido S, Steinkasserer A, Klein L.
J Exp Med. 2016 Aug 22;213(9):1685-94. doi: 10.1084/jem.20160316. Epub 2016 Aug 8. PMID: 27503071
CD83 Modulates B Cell Activation and Germinal Center Responses.
Krzyzak L, Seitz C, Urbat A, Hutzler S, Ostalecki C, Gläsner J, Hiergeist A, Gessner A, Winkler TH, Steinkasserer A, Nitschke L.
J Immunol. 2016 May 1;196(9):3581-94. doi: 10.4049/jimmunol.1502163. Epub 2016 Mar 16.PMID: 26983787
Research & progress – summarized for you.
Our newsletter keeps you well informed regarding new findings and pioneering developments.
